BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG–ACRIN Cancer Research Group (E2804)

PURPOSE: On the basis of evidence that resistance to vascular endothelial growth factor (VEGF) receptor inhibition is caused by hypoxia-driven residual VEGF and other proangiogenic factors, combinations of agents from these classes were hypothesized to improve treatment outcomes relative to single-a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Oncol
Hauptverfasser: Flaherty, Keith T., Manola, Judith B., Pins, Michael, McDermott, David F., Atkins, Michael B., Dutcher, Janice J., George, Daniel J., Margolin, Kim A., DiPaola, Robert S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2015
Schlagworte:
ORIGINAL REPORTS
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4500832/
https://ncbi.nlm.nih.gov/pubmed/26077237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.60.9727
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge